<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00203762</url>
  </required_header>
  <id_info>
    <org_study_id>IDRC 102770-001</org_study_id>
    <nct_id>NCT00203762</nct_id>
  </id_info>
  <brief_title>Effect of Public Sector Antiretroviral Treatment Programme on Tuberculosis and Immunization Care</brief_title>
  <official_title>Effect of the South African Public Sector Antiretroviral Treatment Programme on the Performance of Tuberculosis and Immunization Programmes - A Cluster Controlled (Non-Randomized) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Free State Department of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Council, South Africa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Knowledge Translation Programme, University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute for Clinical Evaluative Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of the Western Cape</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cape Town</source>
  <brief_summary>
    <textblock>
      A scale-up of public sector antiretroviral treatment (ART) programmes may divert scarce&#xD;
      resources from other priority primary care programmes like tuberculosis and childhood&#xD;
      immunization.&#xD;
&#xD;
      The purpose of this study is to compare the performance of tuberculosis (TB) and childhood&#xD;
      immunization programmes in primary care facilities participating in the South African&#xD;
      national antiretroviral treatment programme with those which have yet to be included in the&#xD;
      ART programme.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Large-scale public sector antiretroviral treatment programmes, like those planned for&#xD;
      sub-Saharan Africa, will compete for scarce resources, in particular scarce human resources,&#xD;
      with other priority primary care programmes like tuberculosis and childhood immunization.&#xD;
&#xD;
      This could lead to impaired performance in other priority programmes like childhood&#xD;
      immunization while health workers are distracted by the demands of establishing and&#xD;
      maintaining ART programmes. On the other hand, ART provisions may have positive spin-offs for&#xD;
      related programmes like improved case detection of tuberculosis among HIV-positive patients&#xD;
      seeking ART. The impact of the ART programme on primary healthcare more generally must be&#xD;
      weighed against the benefits of providing antiretroviral treatment to those with AIDS.&#xD;
&#xD;
      Comparison: Primary care clinics in the Free State province, South Africa. 15 clinics&#xD;
      participating in the first phases of the national ART programme will be compared with 24&#xD;
      clinics which have yet to be included in the national treatment programme. The unit of&#xD;
      analysis will be the clinic although the outcome data will be collected from individual&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2003</start_date>
  <completion_date>December 2006</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TB case detection</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>TB treatment completion</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Measles immunization completed by 18 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>TB cure rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TB mortality rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TB treatment failure rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TB treatment interruption rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of TB cases that smear positive</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Tuberculosis</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Public sector antiretroviral treatment programmes</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Clinics:&#xD;
&#xD;
          -  Intervention: 15 primary care clinics participating in the first phases of the&#xD;
             national antiretroviral treatment programme&#xD;
&#xD;
          -  Control: 24 primary care clinics yet to be included in the national antiretroviral&#xD;
             treatment programme randomly selected after stratification for health district and&#xD;
             ranking of clinic size.&#xD;
&#xD;
        Patients:&#xD;
&#xD;
          -  All patients attending tuberculosis and childhood immunization programmes at the above&#xD;
             39 clinics one year before and one year after antiretroviral treatment services&#xD;
             commenced in these facilities.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Clinics:&#xD;
&#xD;
          -  Clinics earmarked for the second year of the rollout of the antiretroviral treatment&#xD;
             programme.&#xD;
&#xD;
        Patients:&#xD;
&#xD;
          -  None.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>L R Fairall, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cape Town Lung Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>L R Fairall, MBChB</last_name>
    <phone>+27 21 4066919</phone>
    <phone_ext>6919</phone_ext>
    <email>lfairall@uctgsh1.uct.ac.za</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>G M Rembe, BSc(Hons)</last_name>
    <phone>+27 21 4066928</phone>
    <phone_ext>6928</phone_ext>
    <email>grembe@uctgsh1.uct.ac.za</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Cape Town Lung Institute</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7937</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L R Fairall, MBChB</last_name>
      <phone>+27 21 4066919</phone>
      <phone_ext>6919</phone_ext>
      <email>lfairall@uctgsh1.uct.ac.za</email>
    </contact>
    <contact_backup>
      <last_name>G M Rembe, BSc(Hons)</last_name>
      <phone>+27 21 4066928</phone>
      <phone_ext>6928</phone_ext>
      <email>grembe@uctgsh1.uct.ac.za</email>
    </contact_backup>
    <investigator>
      <last_name>L R Fairall, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>March 2004</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>October 23, 2007</last_update_submitted>
  <last_update_submitted_qc>October 23, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2007</last_update_posted>
  <keyword>Pragmatic cluster non-randomized controlled trial</keyword>
  <keyword>antiretroviral treatment</keyword>
  <keyword>tuberculosis</keyword>
  <keyword>childhood immunization</keyword>
  <keyword>primary care</keyword>
  <keyword>resource-restricted settings</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Retroviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

